ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

REPL Replimune Group Inc

6.95
0.39 (5.95%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Replimune Group Inc REPL NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.39 5.95% 6.95 10:00:00
Open Price Low Price High Price Close Price Previous Close
6.80 6.605 7.08 6.95 6.56
more quote information »

Recent News

Date Time Source Heading
08/4/202407:00GLOBEInterim Results from the ARTACUS Clinical Trial of RP1..
04/4/202423:00GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
26/3/202422:30GLOBEReplimune Announces Appointment of Sushil Patel to CEO and..
07/3/202400:00GLOBEReplimune to Present at the American Association for Cancer..
06/3/202400:00GLOBEReplimune to Present at Three Upcoming Investor Conferences
14/2/202423:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202400:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/2/202400:05EDGAR2Form 8-K - Current report
09/2/202400:00GLOBEReplimune Reports Fiscal Third Quarter 2024 Financial..
16/1/202420:06PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
16/1/202419:59PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
09/1/202400:00EDGAR2Form 8-K - Current report
29/12/202300:00GLOBEReplimune to Present at the 42nd Annual J.P. Morgan..
27/12/202309:15EDGAR2Form 8-K - Current report
05/12/202323:19EDGAR2Form 8-K - Current report
05/12/202323:00GLOBEReplimune Shares Initial Primary Analysis Results from..
18/11/202312:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202312:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202301:10GLOBEReplimune Presents Updated Data on RP2 in Uveal Melanoma..
08/11/202309:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202300:15EDGAR2Form 8-K - Current report
08/11/202300:00GLOBEReplimune Reports Fiscal Second Quarter 2024 Financial..
04/11/202310:30GLOBEReplimune Presents Updated Interim Results from the ARTACUS..
21/9/202310:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202310:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/9/202306:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
19/9/202322:15EDGAR2Form 8-K - Current report
19/9/202322:00GLOBEReplimune Announces Appointment of Emily Hill as Chief..
14/9/202311:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202323:17EDGAR2Form 8-K - Current report
25/8/202310:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202310:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202323:04EDGAR2Form 8-K - Current report
03/8/202322:45EDGAR2Form S-3ASR - Automatic shelf registration statement of..
03/8/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:09EDGAR2Form 8-K - Current report
03/8/202322:00GLOBEReplimune Reports Fiscal First Quarter 2024 Financial..
01/8/202322:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
01/8/202306:01BWReplimune and Incyte Enter into Clinical Trial Collaboration..
27/7/202310:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/7/202307:08EDGAR2Form ARS - Annual Report to Security Holders
27/7/202307:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
27/7/202307:02EDGAR2Form DEF 14A - Other definitive proxy statements
20/7/202322:56EDGAR2Form 8-K - Current report
20/7/202322:00GLOBEReplimune Announces Sander Slootweg will Depart from its..
12/7/202311:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/7/202306:27EDGAR2Form 144 - Report of proposed sale of securities
07/6/202300:00GLOBEReplimune Presents Initial RP1 Data from the ARTACUS..
05/6/202322:00GLOBEReplimune Appoints Veleka R. Peeples-Dyer to its Board of..
04/6/202304:15GLOBEReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed..

Your Recent History

Delayed Upgrade Clock